Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.
about
Infiltrative CardiomyopathiesEffects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry diseaseAn open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease.Inter-familial and intra-familial phenotypic variability in three Sicilian families with Anderson-Fabry disease.Limited effects of long-term enzyme replacement therapy on the cardiac conduction system in Fabry disease
P2860
Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.
@en
Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.
@nl
type
label
Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.
@en
Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.
@nl
prefLabel
Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.
@en
Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.
@nl
P2093
P2860
P921
P1476
Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.
@en
P2093
E R Schwarz
K J Philip
R P Morrissey
P2860
P5008
P577
2011-01-01T00:00:00Z